ImaginAb has raised an additional $8 million in new equity funding led by Adage Capital. The company’s shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech Invest, and Jim Pallotta of the Raptor Group.
ImaginAb Inc. Announces Strategic Collaboration with Boehringer Ingelheim to Develop New Technology for Monitoring Anti-tumor Activity of the Immune System
ImaginAb announced today a collaboration with Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies, to further develop ImaginAb’s CD8 T Cell imaging technology.
ImaginAb Inc. today announced the appointment of Martyn Coombs as Chief Executive Officer.